XENETIC BIOSCIENCES, INC. Repayments of Debt
XENETIC BIOSCIENCES, INC. (XBIO) reported Repayments of Debt of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:RepaymentsOfDebt · last filed 2018-03-30
- XENETIC BIOSCIENCES, INC. repayments of debt for the quarter ending 2015-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. repayments of debt for the quarter ending 2014-12-31 was $0.00.
- XENETIC BIOSCIENCES, INC. repayments of debt for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- XENETIC BIOSCIENCES, INC. repayments of debt for fiscal 2016 was $369.96K, a 269.96% increase from fiscal 2015.
- XENETIC BIOSCIENCES, INC. repayments of debt for fiscal 2015 was $100.00K.
- XENETIC BIOSCIENCES, INC. repayments of debt for fiscal 2014 was $0.00.
| Period end | Repayments of Debt 3 month | Repayments of Debt 9 month | Repayments of Debt 12 month |
|---|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-30 | ||
| 2016-12-31 | $369.96K 10-K · filed 2018-03-30 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $100.00K 10-K · filed 2017-03-31 | |
| 2015-09-30 | $100.00K 10-Q · filed 2015-11-16 | ||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $0.00 10-K · filed 2016-03-30 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |